Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report

Upper tract urothelial carcinoma (UTUC) is often diagnosed late and exhibits poor prognosis. Only limited data are available concerning therapeutic regimes and potential biomarkers for disease monitoring. Standard therapies often provide only insufficient treatment options. Hence, immunotherapies an...

Descripción completa

Detalles Bibliográficos
Autores principales: Blumendeller, Carolin, Boehme, Julius, Frick, Maximilian, Schulze, Martin, Rinckleb, Antje, Kyzirakos, Christina, Kayser, Simone, Kopp, Maria, Kelkenberg, Sabine, Pieper, Natalia, Bartsch, Oliver, Hadaschick, Dirk, Battke, Florian, Stenzl, Arnulf, Biskup, Saskia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802705/
https://www.ncbi.nlm.nih.gov/pubmed/33431630
http://dx.doi.org/10.1136/jitc-2020-001406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802705/
https://www.ncbi.nlm.nih.gov/pubmed/33431630
http://dx.doi.org/10.1136/jitc-2020-001406

Ejemplares similares